World Journal of Urology

, Volume 25, Issue 1, pp 73–80 | Cite as

Association of EMMPRIN and fascin expression in renal cell carcinoma: correlation with clinicopathological parameters

  • Wen-Chiuan Tsai
  • Lai-Fa Sheu
  • Shin Nieh
  • Cheng-Ping Yu
  • Gung-Huan Sun
  • Yeh-Feng Lin
  • Ann Chen
  • Jong-Shiaw Jin
Original Article


EMMPRIN and fascin are important factors in tumor invasion and progression. We tested the hypothesis that expression of EMMPRIN and fascin correlate with clinicopathological parameters of renal cell carcinoma (RCC). Immunohistochemical analysis of EMMPRIN and fascin were performed in tissue microarrays of 100 surgical specimens, including 35 clear-cell RCC (CRCC), 21 clear-cell RCC with granular differentiation (GRCC), 12 chromophobe RCC (ChRCC), 8 papillary RCC (PRCC), 9 carcinoma of the collecting duct of Bellini (CDC), 10 clear-cell RCC with sarcomatoid differentiation (SRCC), and 6 metastatic RCC. Average immunoscores of EMMPRIN were 100.8 in CRCC, 195.2 in GRCC, 298.4 in ChRCC, 219.2 in PRCC, 186.1 in CDC, 226.9 in SRCC, and 151.7 in metastatic RCC. Among all included cases, average EMMPRIN immunoscores were 84.6 in grade I, 130.4 in grade II, 184.3 in grade III, and 223.5 in grade IV. Additionally, average immunostaining scores of fascin were 53.6 in CRCC, 289.3 in GRCC, 193.3 in ChRCC, 151.8 in PRCC, 181.3 in CDC, 275.4 in SRCC, and 131.7 in metastatic RCC. Average fascin immunoscores were 59.3 in grade I, 91.6 in grade II, 130.2 in grade III, and 194.7 in grade IV. Higher EMMPRIN and fascin immunoscores also correlated significantly with TNM stages and survival rates in RCC. Significant correlation was found between EMMPRIN and fascin expression. In conclusion, higher expression of EMMPRIN and fascin correlate significantly with histological grades, clinical stages, and survival rates of RCC


Renal cell carcinoma EMMPRIN Fascin Immunostaining scores Survival test 



This study was supported by grants from National Science Counsel, NSC95-2320-B-016-024, and Tri-Service General Hospital, TSGH-C95-16-S05, Taiwan, R.O.C.


  1. 1.
    Eble JN, Sauter G, Epstein JI, Sesterhenn IA (eds) (2004) World Health Organization classification of tumours. Pathology and genetics of tumors of the urinary system and male genital organs. IARC Press, Lyon, pp 10–34Google Scholar
  2. 2.
    Parkin DM, Pisani P, Lopez AD, Masuyer E (1994) At least one in seven cases of cancer is caused by smoking. Global estimates for 1985. Int J Cancer 59:494–504PubMedCrossRefGoogle Scholar
  3. 3.
    Chen CJ, Chen CW, Wu MM, Kuo TL (1992) Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. Br J Cancer 66:888–892PubMedGoogle Scholar
  4. 4.
    Ficarra V, Righetti R, Martignoni G, D’Amico A, Pilloni S, Rubilotta E, Malossini G, Mobilio G (2001) Prognostic value of renal cell carcinoma nuclear grading: multivariate analysis of 333 cases. Urol Int 67:130–134PubMedCrossRefGoogle Scholar
  5. 5.
    Srigley JR, Hutter RV, Gelb AB, Henson DE, Kenney G, King BF, Raziuddin S, Pisansky TM (1997) Current prognostic factors—renal cell carcinoma: workgroup no. 4. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80:994–996PubMedCrossRefGoogle Scholar
  6. 6.
    Flanigan RC (2004) Debulking nephrectomy in metastatic renal cancer. Clin Cancer Res 10:6335S–6341SPubMedCrossRefGoogle Scholar
  7. 7.
    Guo H, Li R, Zucker S, Toole BP (2000) EMMPRIN (CD147), an inducer of matrix metalloproteinase synthesis, also binds interstitial collagenase to the tumor cell surface. Cancer Res 60(4):888–891PubMedGoogle Scholar
  8. 8.
    Chambers AF, Matrisian LM (1997) Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89:1260–1270PubMedCrossRefGoogle Scholar
  9. 9.
    Biswas C, Zhang Y, DeCastro R, Guo H, Nakamura T, Kataoka H, Nabeshima K (1995) The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 55(2):434–439PubMedGoogle Scholar
  10. 10.
    Himelstein BP, Canete-Soler R, Bernhard EJ, Muschel RJ (1994) Induction of fibroblast 92 kDa gelatinase/type IV collagenase expression by direct contact with metastatic tumor cells. J Cell Sci 107:477–486PubMedGoogle Scholar
  11. 11.
    Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limacher JM, Podhajcer OL, Chenard MP, Rio MC, Chambon P (1990) A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 348(6303):699–704PubMedCrossRefGoogle Scholar
  12. 12.
    Okada A, Bellocq JP, Rouyer N, Chenard MP, Rio MC, Chambon P, Basset P (1995) Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci USA 92(7):2730–2734PubMedCrossRefGoogle Scholar
  13. 13.
    Riethdorf S, Reimers N, Assmann V, Kornfeld JW, Terracciano L, Sauter G, Pantel K (2006) High incidence of EMMPRIN expression in human tumors. Int J Cancer (in press)Google Scholar
  14. 14.
    Jin JS, Hsieh DS, Lin YF, Wang JY, Sheu LF, Lee WH (2006) Increasing expression of extracellular matrix metalloprotease inducer in renal cell carcinoma: tissue microarray analysis of immunostaining score with clinicopathological parameters. Int J Urol 13:573–580PubMedCrossRefGoogle Scholar
  15. 15.
    Adams JC (2004) Roles of fascin in cell adhesion and motility. Curr Opin Cell Biol 16:590–596PubMedCrossRefGoogle Scholar
  16. 16.
    Duh FM, Latif F, Weng Y, Geil L, Modi W, Stackhouse T, Matsumura F, Duan DR, Linehan WM, Lerman MI et al (1994) cDNA cloning and expression of the human homolog of the sea urchin fascin and Drosophila singed genes which encodes an actin-bundling protein. DNA Cell Biol 13:821–827PubMedCrossRefGoogle Scholar
  17. 17.
    Grothey A, Hashizume R, Sahin AA, McCrea PD (2000) Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breast cancer. Br J Cancer 83:870–873PubMedCrossRefGoogle Scholar
  18. 18.
    Roma AA, Prayson RA (2005) Fascin expression in 90 patients with glioblastoma multiforme. Ann Diagn Pathol 9:307–311PubMedCrossRefGoogle Scholar
  19. 19.
    Xie JJ, Xu LY, Zhang HH, Cai WJ, Mai RQ, Xie YM, Yang ZM, Niu YD, Shen ZY, Li EM (2005) Role of fascin in the proliferation and invasiveness of esophageal carcinoma cells. Biochem Biophys Res Commun 337:355–362PubMedCrossRefGoogle Scholar
  20. 20.
    Hashimoto Y, Shimada Y, Kawamura J, Yamasaki S, Imamura M (2004) The prognostic relevance of fascin expression in human gastric carcinoma. Oncology 67:262–270PubMedCrossRefGoogle Scholar
  21. 21.
    Pelosi G, Pastorino U, Pasini F, Maissoneuve P, Fraggetta F, Iannucci A, Sonzogni A, De Manzoni G, Terzi A, Durante E, Bresaola E, Pezzella F, Viale G (2003) Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer. Br J Cancer 88:537–547PubMedCrossRefGoogle Scholar
  22. 22.
    Tong GX, Yee H, Chiriboga L, Hernandez O, Waisman J (2005) Fascin-1 expression in papillary and invasive urothelial carcinomas of the urinary bladder. Hum Pathol 36:741–746PubMedCrossRefGoogle Scholar
  23. 23.
    Yang JM, Xu Z, Wu H, Zhu H, Wu X, Hait WN (2003) Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells. Mol Cancer Res 1:420–427PubMedGoogle Scholar
  24. 24.
    Yan L, Zucker S, Toole BP (2005) Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb Haemost 93:199–204PubMedGoogle Scholar
  25. 25.
    Adams JC (2004) Fascin protrusions in cell interactions. Trends Cardiovasc Med 14:221–226PubMedCrossRefGoogle Scholar
  26. 26.
    Hashimoto Y, Skacel M, Adams JC (2005) Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker? Int J Biochem Cell Biol 37:1787–1804PubMedCrossRefGoogle Scholar
  27. 27.
    Swierczynski SL, Maitra A, Abraham SC, Iacobuzio-Donahue CA, Ashfaq R, Cameron JL, Schulick RD, Yeo CJ, Rahman A, Hinkle DA, Hruban RH, Argani P (2004) Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum Pathol 35:357–366PubMedCrossRefGoogle Scholar
  28. 28.
    Jawhari AU, Buda A, Jenkins M, Shehzad K, Sarraf C, Noda M, Farthing MJ, Pignatelli M, Adams JC (2003) Fascin, an actin-bundling protein, modulates colonic epithelial cell invasiveness and differentiation in vitro. Am J Pathol 162:69–80PubMedGoogle Scholar
  29. 29.
    Hu W, McCrea PD, Deavers M, Kavanagh JJ, Kudelka AP, Verschraegen CF (2000) Increased expression of fascin, motility associated protein, in cell cultures derived from ovarian cancer and in borderline and carcinomatous ovarian tumors. Clin Exp Metastasis 18:83–88PubMedCrossRefGoogle Scholar
  30. 30.
    Nabeshima K, Iwasaki H, Koga K, Hojo H, Suzumiya J, Kikuchi M (2006) Emmprin (basigin/CD147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol Int 56:359–367PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Wen-Chiuan Tsai
    • 1
  • Lai-Fa Sheu
    • 1
  • Shin Nieh
    • 1
  • Cheng-Ping Yu
    • 1
  • Gung-Huan Sun
    • 2
  • Yeh-Feng Lin
    • 3
  • Ann Chen
    • 1
  • Jong-Shiaw Jin
    • 1
  1. 1.Department of PathologyTri-Service General Hospital, National Defense Medical CenterTaipeiTaiwan
  2. 2.Division of Urology, Department of SurgeryTri-Service General Hospital, National Defense Medical CenterTaipeiTaiwan
  3. 3.Division of Nephrology, Department of Internal Medicine Tri-Service General Hospital, National Defense Medical CenterTaipeiTaiwan

Personalised recommendations